FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to intensive care and resuscitation, and can be used for treating patients with a new coronavirus infection (COVID-19). Method involves intravenous introduction of a serotonin adipinate solution at rate of 10–30 mg/h to the patients with a new coronaviral infection COVID-19 with respiratory failure on respiratory support. Respiratory support is non-invasive lung ventilation, oxygen therapy; additionally, calcium nandroparin or enoxaparine are administered.
EFFECT: using the invention enables improving the oxygenating function of the lungs by normalizing smooth muscle function of the microcirculatory bed of the lungs and other organs, and thereby increasing gas exchange.
1 cl, 3 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR IMPROVING OXYGENATING PULMONARY FUNCTION IN PATIENTS WITH RESPIRATIVE INSUFFICIENCY BEING UPON CONTROLLED VENTILATION | 2003 |
|
RU2245139C1 |
| METHOD FOR OXYGEN THERAPY DURING SPONTANEOUS BREATHING IN CORONAVIRUS INFECTION | 2022 |
|
RU2787834C1 |
| METHOD FOR COVID-19 PNEUMONIA TREATMENT | 2020 |
|
RU2745535C1 |
| METHOD OF CHOOSING TACTICS FOR CORRECTING ACUTE RESPIRATORY FAILURE IN PATIENTS WITH COVID-19 | 2023 |
|
RU2807934C1 |
| METHOD FOR THE TREATMENT OF RESPIRATORY FAILURE AFTER ACUTE RESPIRATORY DISTRESS SYNDROME, REGARDLESS OF ETIOLOGY | 2022 |
|
RU2782103C1 |
| METHOD OF DIAGNOSING IMPAIRMENT OF BLOOD OXYGENATION IN PROCESS OF ARTIFICIAL LUNG VENTILATION | 2011 |
|
RU2457781C1 |
| METHOD OF RESPIRATORY THERAPY IN NEW CORONAVIRUS INFECTION COVID-19 IN PATIENTS WITH RESPIRATORY FAILURE, WHO ARE ON SPONTANEOUS BREATHING | 2021 |
|
RU2769489C1 |
| METHOD FOR PREDICTING THE LETHAL OUTCOME IN PATIENTS WITH SEVERE CoVID-19 | 2021 |
|
RU2780748C1 |
| METHOD OF PREDICTING THE RISK OF DEATH FROM COVID-19 IN YOUNG PATIENTS | 2023 |
|
RU2803002C1 |
| METHOD OF TREATING COVID-19 IN CHILDREN AT RISK OF SEVERE CLINICAL COURSE OF DISEASE | 2023 |
|
RU2815303C1 |
